Edoc Acquisition Corp. Class A Ordinary Share (ADOC): Price and Financial Metrics


Edoc Acquisition Corp. Class A Ordinary Share (ADOC): $10.39

-0.01 (-0.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ADOC Stock Price Chart Interactive Chart >

Price chart for ADOC

ADOC Price/Volume Stats

Current price $10.39 52-week high $11.60
Prev. close $10.40 52-week low $10.00
Day low $10.39 Volume 5,900
Day high $10.40 Avg. volume 27,568
50-day MA $10.31 Dividend yield N/A
200-day MA $10.21 Market Cap 50.19M


ADOC Latest News Stream


Event/Time News Detail
Loading, please wait...

ADOC Latest Social Stream


Loading social stream, please wait...

View Full ADOC Social Stream

Latest ADOC News From Around the Web

Below are the latest news stories about EDOC ACQUISITION CORP that investors may wish to consider to help them evaluate ADOC as an investment opportunity.

EDOC Acquisition Corp. Announces Voting Results of Extraordinary General Meeting to Approve the Extension Amendment

New York, NY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, “EDOC” or the “Company”), a special purpose acquisition company, announced today that the Company’s shareholders voted in favor of the proposal to amend its charter (the “Extension Amendment”) to extend the date by which the Company has to complete a business combination from August 12, 2022 to February 12, 2023 (the “Extension”), at the extraordinary general meeting of EDOC shareholders that took

Yahoo | August 15, 2022

Edoc Acquisition Corp. Announces Termination of Merger Agreement with Calidi Biotherapeutics, Inc.

New York, NY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, “EDOC” or the “Company”), a special purpose acquisition company, announced today the termination of its previously announced agreement and plan of merger (the “Merger Agreement”) with Calidi Biotherapeutics, Inc. (“Calidi”). Although Edoc and Calidi may continue to discuss the possibility of engaging in a business combination, there can be no assurance that those discussions will result in a trans

Yahoo | August 12, 2022

Edoc Acquisition Corp. Announce Postponement of Special Meeting of Shareholders to Extend the Deadline to Consummate an Initial Business Combination

● Extraordinary General Meeting of Edoc’s shareholders postponed until August 12, 2022, at 8:00 p.m., Eastern Time NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, “EDOC” or the “Company”), today announced the postponement of Edoc’s extraordinary general meeting of shareholders (the “Special Meeting”) originally scheduled to be held on August 12, 2022 at 10:00 am Eastern Time. The Special Meeting has been postponed until August 12, 2022 at 8:00 p.m.

Yahoo | August 12, 2022

Edoc Acquisition Corp. Reminds Shareholders to Vote and Announces Additional Contribution for Extension Amendment

NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, “EDOC” or the “Company”) encourages its shareholders to vote in favor of the proposal to amend its charter (the “Extension Amendment”) to extend the date by which the Company has to complete a business combination from August 12, 2022 to February 12, 2023 (the “Extension”). An extraordinary general meeting of the Company’s shareholders (“Special Meeting”) to approve the Extension Amendment will be hel

Yahoo | August 4, 2022

ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao

LYON, France, April 11, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the final approval by the German (BfArM) regulatory authorities to conduct three clinical studies on BioChaperone® Combo ("BC Combo").

Yahoo | April 11, 2022

Read More 'ADOC' Stories Here

ADOC Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 1.96%
3-year N/A
5-year N/A
YTD N/A
2021 0.00%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8319 seconds.